Innophore VC Deck 2024 Customer Segments Drug Design Repurposing

Introduction

Firstly, Innophore is an Austrian biotechnology and AI player headquartered in Graz & this firm specializes in computational drug discovery, with enzyme research. This is often known as ‘Google for enzymers ', as its patented Catalophore platform treats 3D protein cavities as searchable fingerprints to scan across nature at unusual speeds.

Innophore VC deck 2024 was established to secure institutional funding to expand their AI-powered drug discovery, safety screening, & enzyme engineering platforms. This advanced the company as a key leader in the generative AI and computational biology sector.

Whereas AI is playing a pivotal role in the global & Innophores’s drug discovery areas, AI supports structural biology with vast computational power & significant speed up drug discovery. The use of AI models in the organization fosters accelerated mapping of protein binding sites, prediction of ff-target interactions, & screening of millions of molecular entities.

About Innophore

Decades ago, Innophore’s research labs in Graz, Austria, showed one idea that includes protein, along with the most important protein binding sites. Innophore is highly focused on enzyme discovery, drug repurposing, & safety screening by the players in pharma, biotech and the chemical industry. Innophore unveiled its integrated patent CatalophoreTM technology to state-of-the-art conventional bioinformatics approaches. They leverage AI to extract structural and sequence databases employing three-dimensional (3D) search templates called ‘catalophores’ described by point clouds of physicochemical characteristics.

Customer Segments

Customers need & challenges

Primarily, different customer groups are highly demanding highly specific, stable, and active enzymes for industrial biotechnology, which requires biocatalysts to conduct at highly specific conditions by skipping traditional trial-and-error organism modeling. Moreover, many pharma customers are unveiling the need to find functional correlations between biomolecules to overcome off-target effects, & this will support predicting side effects & ensuring drug safety before entering expensive pre-clinical studies.

On the other side of the page, these emerging & developed customer groups are facing certain key challenges, like slow & lengthy R&D cycles, as 90% of drugs in these stages fail because of noted toxicity or minimal efficacy. Alongside, a dependency on traditional bioinformatics to compare gene sequences leads to a loss of vital functional connections between biomolecules.

To meet these needs & resolve the challenges, Innophore provides advanced solutions:

Innophore’s key customer groups include giant pharma leaders & biotech startups that can employ Innophore’s computational tools to perform in silico target discovery, predict off-target toxicities, map the human proteome, & expedite the identification of drug repurposing candidates. Apart from this, other customers, mainly in food, fine chemical, & other industrial areas, are applying Innophore's structural biology engine to find & enhance specialized enzymes, which allows the development of green manufacturing processes.

Catalophore platform- Drug Design Solution

This is an AI-assisted 3D point-cloud technology that enables mapping and scanning of protein cavities & binding sites, and further serves as a ‘search engine for enzymes' that allows biotech and pharma players to foster drug discovery, safety screening, and enzyme engineering.

Innophore has expanded four major offerings of this platform, such as,

Catalophore Platform Pro

This platform is a full-scale, on-site workspace allocated behind their corporate firewall, which gives local control over all sequences, structures, cavities, & compute data.

Catalophore Studio

This platform translates raw protein structures into interpreted binding sites in seconds through the integration of point-cloud cavity detection, physicochemical property fields, & ligand docking.

CavitOmiX

A known AI-driven off-target search tool created in collaboration with NVIDIA that estimates drug side effects and maps off-target binding across the human proteome.

Catalophore for PyMOL

This solution introduces Innophore’s cavity analysis and 3D matching directly into the commonly employed PyMOL viewing software.

Drug Repurposing & Innophore’s Support

The process of finding new therapeutic applications of existing drugs that are already approved by the FDA or clinically tested is referred to as drug repurposing. In this case, Innophore is assisting in the scanning of comprehensive proteomes via the assessment of the accurate shape and chemical properties of protein cavities & active sites.

The ongoing pipeline of CavitOmix is fostering rapid screening of databases of approved drugs to find structural matches for new target proteins. Further, this enables researchers to expedite identification, as existing medications might inhibit a newly mutated virus or disease protein.

How are AI & Computational Technologies Empowering Innophore?

Day by day, Innophore is promoting innovation by using AI & computational models that mainly integrate Innophore’s unique cavity-analysis methods with deep learning to strengthen specialized pharma and biotech pipelines. Besides this, AI adoption is supporting the alterations of ligands with increased paralog-level selectivity, which confirms that drugs hit the correct targets without causing unnecessary side effects. Innophore’s prominent platform allows an evaluation of extended surface properties (HALOS). This assists in anticipating protein characteristics and reactivity accurately, speeding up the discovery of protein candidates that operate in specific, real-world industrial circumstances.

Business Strategies of Innophore

Innophore’s revenue model is mainly operating on a B2B customized services model that monetises their proprietary Catalophore platform through specific, phased engagement tracks for biotechnology and pharmaceutical firms, ensuring all generated intellectual property is protected. Innophore is promoting fixed-scope projects with elucidated deliverables ranging from six to 12 weeks. This model is exploring full-time equivalent (FTE) contracts, where customers pay for continuous assignments of scientific personnel for repeat enzyme campaigns, which are renewed each year.

Innophore is executing diverse collaborations with major & emerging companies, including.

A prominent alliance of Innophore is made with NVIDIA Healthcare & Life Sciences, on the unification of NVIDIA’s BioNeMo platform and cloud APIs into their Catalophore architecture. This alliance further jointly developed a proteome-wide structural dataset in two weeks, a task that previously needed over a year.

• In the pharma & chemicals sector, Innophore joined with Merck for virtual screening, drug repurposing, and off-target toxicity validation.
• Innophore has empowered its partnership with Henkel to find and design customized industrial enzymes for everyday products.

Ongoing Trends & Future Opportunities in Drug Design Repurposing Sector

The worldwide companies are widely using tools, such as AutoDock & SwissDock, for expressing how developed pharmaceutical molecules fit into target proteins associated with various diseases. Nowadays, oncology is the most spotlighted area, while cancer drugs are broadening their applications across infectious diseases. However, anti-inflammatory and metabolic drugs are being repurposed for complex diseases, such as Alzheimer's or autoimmune conditions. In the coming era, the industry will reinforce the applications of advanced AI algorithms & in silico drug design tools, especially through massive genomic, transcriptomic, and clinical databases in weeks to predict completely new drug-target interactions.

Conclusion

An Austrian biotech leader is known as Innophore, which mainly operates a digital ‘search engine for the molecular world’. They have provided different services to various companies, especially for biotech companies. Innophore offers industrial enzymes to process their thermostability, pH range, selectivity or activity on a non-native substrate. For pharma companies, Innophore is offering advanced platforms for hit identification, drug repurposing, proteome-wide off-target screening & biocatalysis, and binding site first. To bolster drug repurposing & the prediction of side effects, Innophore is working on 3D point-cloud technology.